NVAX
Price
$8.64
Change
-$0.02 (-0.23%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
1.41B
42 days until earnings call
PPTDF
Price
$11.81
Change
+$0.81 (+7.36%)
Updated
Sep 16 closing price
Capitalization
1.45B
Interact to see
Advertisement

NVAX vs PPTDF

Header iconNVAX vs PPTDF Comparison
Open Charts NVAX vs PPTDFBanner chart's image
Novavax
Price$8.64
Change-$0.02 (-0.23%)
Volume$22.93K
Capitalization1.41B
Peptidream
Price$11.81
Change+$0.81 (+7.36%)
Volume$1.3K
Capitalization1.45B
NVAX vs PPTDF Comparison Chart in %
Loading...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PPTDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NVAX vs. PPTDF commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVAX is a Buy and PPTDF is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (NVAX: $8.67 vs. PPTDF: $11.81)
Brand notoriety: NVAX: Notable vs. PPTDF: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NVAX: 55% vs. PPTDF: 120%
Market capitalization -- NVAX: $1.41B vs. PPTDF: $1.45B
NVAX [@Biotechnology] is valued at $1.41B. PPTDF’s [@Biotechnology] market capitalization is $1.45B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVAX’s FA Score shows that 1 FA rating(s) are green whilePPTDF’s FA Score has 0 green FA rating(s).

  • NVAX’s FA Score: 1 green, 4 red.
  • PPTDF’s FA Score: 0 green, 5 red.
According to our system of comparison, NVAX is a better buy in the long-term than PPTDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVAX’s TA Score shows that 5 TA indicator(s) are bullish while PPTDF’s TA Score has 3 bullish TA indicator(s).

  • NVAX’s TA Score: 5 bullish, 4 bearish.
  • PPTDF’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, NVAX is a better buy in the short-term than PPTDF.

Price Growth

NVAX (@Biotechnology) experienced а +1.29% price change this week, while PPTDF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was +10.70%, and the average quarterly price growth was +54.52%.

Reported Earning Dates

NVAX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PPTDF($1.45B) and NVAX($1.41B) have the same market capitalization . PPTDF has higher P/E ratio than NVAX: PPTDF (14.56) vs NVAX (3.91). NVAX YTD gains are higher at: 7.836 vs. PPTDF (-33.838). NVAX has higher annual earnings (EBITDA): 496M vs. PPTDF (-3.66B). PPTDF has more cash in the bank: 33.3B vs. NVAX (612M). NVAX has less debt than PPTDF: NVAX (228M) vs PPTDF (18.3B). PPTDF has higher revenues than NVAX: PPTDF (19.1B) vs NVAX (1.08B).
NVAXPPTDFNVAX / PPTDF
Capitalization1.41B1.45B97%
EBITDA496M-3.66B-14%
Gain YTD7.836-33.838-23%
P/E Ratio3.9114.5627%
Revenue1.08B19.1B6%
Total Cash612M33.3B2%
Total Debt228M18.3B1%
FUNDAMENTALS RATINGS
NVAX vs PPTDF: Fundamental Ratings
NVAX
PPTDF
OUTLOOK RATING
1..100
2131
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
87
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
4560
P/E GROWTH RATING
1..100
11100
SEASONALITY SCORE
1..100
90n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVAX's Valuation (82) in the Biotechnology industry is in the same range as PPTDF (87) in the null industry. This means that NVAX’s stock grew similarly to PPTDF’s over the last 12 months.

NVAX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PPTDF (100) in the null industry. This means that NVAX’s stock grew similarly to PPTDF’s over the last 12 months.

PPTDF's SMR Rating (99) in the null industry is in the same range as NVAX (100) in the Biotechnology industry. This means that PPTDF’s stock grew similarly to NVAX’s over the last 12 months.

NVAX's Price Growth Rating (45) in the Biotechnology industry is in the same range as PPTDF (60) in the null industry. This means that NVAX’s stock grew similarly to PPTDF’s over the last 12 months.

NVAX's P/E Growth Rating (11) in the Biotechnology industry is significantly better than the same rating for PPTDF (100) in the null industry. This means that NVAX’s stock grew significantly faster than PPTDF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVAXPPTDF
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 2 days ago
50%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
43%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
21%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
40%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
28%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
30%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
N/A
Declines
ODDS (%)
Bearish Trend 30 days ago
89%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
60%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PPTDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NWAYX14.330.08
+0.56%
Nationwide GQG US Quality Eq Eagle
MGLRX16.800.05
+0.30%
MFS Global Real Estate R6
HEIIX13.80N/A
N/A
Hennessy Equity and Income Institutional
HGIFX59.30-0.37
-0.62%
Hartford Core Equity F
PCLCX20.20-0.22
-1.08%
PACE Large Co Growth Equity P

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with MRNA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-2.25%
MRNA - NVAX
50%
Loosely correlated
-2.90%
ARCT - NVAX
40%
Loosely correlated
-3.66%
BNTX - NVAX
40%
Loosely correlated
-0.46%
XNCR - NVAX
37%
Loosely correlated
-0.67%
CRSP - NVAX
36%
Loosely correlated
-2.16%
More

PPTDF and

Correlation & Price change

A.I.dvisor tells us that PPTDF and NVAX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PPTDF and NVAX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PPTDF
1D Price
Change %
PPTDF100%
N/A
NVAX - PPTDF
32%
Poorly correlated
-2.25%
HOTH - PPTDF
28%
Poorly correlated
+6.70%
ADMA - PPTDF
27%
Poorly correlated
-0.31%
VTYX - PPTDF
27%
Poorly correlated
-1.06%
AURA - PPTDF
22%
Poorly correlated
+0.97%
More